Chemistry:Vilanterol

From HandWiki
Short description: Asthma drug – β2 adrenoreceptor agonist
Vilanterol
Vilanterol.svg
Clinical data
License data
Pregnancy
category
  • AU: B3
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC24H33Cl2NO5
Molar mass486.43 g·mol−1
3D model (JSmol)

Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).[1][2]. The combination is also approved for the treatment of asthma in Canada, Europe, Japan[3] and New Zealand.[4]

Vilanterol is available in following combinations:

See also

  • Salmeterol—a long-acting β2 adrenoreceptor agonist (LABA) with a similar backbone.

References

  1. "FDA approves Breo Ellipta to treat chronic obstructive pulmonary disease". https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm351664.htm. 
  2. "Fluticasone furoate/vilanterol: a review of its use in chronic obstructive pulmonary disease". Drugs 74 (13): 1509–22. September 2014. doi:10.1007/s40265-014-0269-6. PMID 25074268. 
  3. "Fluticasone furoate/vilanterol: a review of its use in patients with asthma". Drugs 75 (4): 407–18. March 2015. doi:10.1007/s40265-015-0354-5. PMID 25648266. 
  4. Zealand (www.bka.co.nz), Site designed and developed by bka interactive ltd, Auckland, New (22 June 2019). "Fluticasone and vilanterol | Health Navigator NZ". https://www.healthnavigator.org.nz/medicines/f/fluticasone-plus-vilanterol/.